Sign in

CIK 0000744218 · Large accelerated filer

Celldex Therapeutics, Inc.

Sign in to watch
Ticker
CLDX
Exchange
Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
133191702
Phone
908-200-7500
Business address
53 FRONTAGE ROAD, SUITE 220, HAMPTON, NJ, 08827
Former names
AVANT IMMUNOTHERAPEUTICS INC, T CELL SCIENCES INC
  1. 4 Derivatives Options or other derivatives
  2. 4 Derivatives Options or other derivatives
  3. 4 Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 4 Derivatives Options or other derivatives
  6. 4 Option exercise SVP, CHIEF MEDICAL OFFICER acquired 15,000 shares (option exercise)
  7. 4 Open-market sale SR. VP & CPDO sold 15,000 shares at $35.06 ($525,873)
  8. 4 Open-market sale SVP, CHIEF MEDICAL OFFICER sold 45,000 shares at $35.26 ($1,586,844)
  9. 4 Option exercise SVP & GENERAL COUNSEL acquired 9,540 shares (option exercise)
  10. 4 Open-market sale SVP OF REGULATORY AFFAIRS sold 58,369 shares at $33.65 ($1,964,088)
  11. 4 Open-market sale SR. VP & CCO sold 46,844 shares at an average $33.72 ($1,579,353)
  12. 4 Open-market sale SVP & GENERAL COUNSEL sold 8,006 shares at $33.60 ($269,002)
  13. 4 Open-market sale SVP OF REGULATORY AFFAIRS sold 38,719 shares at $34.07 ($1,319,156)
  14. 4 Open-market sale SVP AND CFO sold 35,000 shares at $34.05 ($1,191,775)
  15. 4 Open-market sale SVP OF CORP AFFAIRS & ADMIN. sold 20,853 shares at $33.73 ($703,334)
  16. 4 Open-market sale SR. VP & CPDO sold 38,597 shares at $33.64 ($1,298,384)
  17. 4 Option exercise SVP & GENERAL COUNSEL acquired 24,166 shares (option exercise)
  18. 4 Option exercise SVP AND CFO acquired 10,750 shares (option exercise)
  19. 4 Derivatives Options or other derivatives
  20. 4 Derivatives Options or other derivatives

Page 4 of 26 · 516 filings